Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review FGFRi are effective treatment strategies for patients with advanced ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met ...
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses Central confirmation of tumor ...
The mutational spectrum of fibroblast growth factor receptor 3 (FGFR3) in individuals with achondroplasia. In humans, the mutations associated with achondroplasia patients are mainly located in ...
TOKYO, Sept 24, 2024 - (JCN Newswire) - - Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements ...
Playing a role in a variety of biological processes, including the promotion of neuronal plasticity, embryonic development, epithelial cell migration, and tumor growth and invasion, basic fibroblast ...
Experiments reveal that a time-dependent epistatic interaction influences how mice respond to opioids, and that intracellular fibroblast growth factors also influence opioid sensitivity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback